Related Experiment Video
Updated: Jul 21, 2025
Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
A Comparative Study of Tumor-Specificity and Neurotoxicity between 3-Styrylchromones and Anti-Cancer Drugs
Tomoyuki Abe1, Hiroshi Sakagami2, Shigeru Amano2
1Division of Geriatric Dentistry, Meikai University School of Dentistry, Saitama 350-0283, Japan.
Abstract:
Background. Many anti-cancer drugs used in clinical practice cause adverse events such as oral mucositis, neurotoxicity, and extravascular leakage. We have reported that two 3-styrylchromone derivatives, 7-methoxy-3-[(1E)-2-phenylethenyl]-4H-1-benzopyran-4-one (Compound A) and 3-[(1E)-2-(4-hydroxyphenyl)ethenyl]-7-methoxy-4H-1-benzopyran-4-one (Compound B), showed the highest tumor-specificity against human oral squamous cell carcinoma (OSCC) cell lines among 291 related compounds. After confirming their superiority by comparing their tumor specificity with newly synthesized 65 derivatives, we investigated the neurotoxicity of these compounds in comparison with four popular anti-cancer drugs. Methods: Tumor-specificity (TSM, TSE, TSN) was evaluated as the ratio of mean CC50 for human normal oral mesenchymal (gingival fibroblast, pulp cell), oral epithelial cells (gingival epithelial progenitor), and neuronal cells (PC-12, SH-SY5Y, LY-PPB6, differentiated PC-12) to OSCC cells (Ca9-22, HSC-2), respectively. Results: Compounds A and B showed one order of magnitude higher TSM than newly synthesized derivatives, confirming its prominent tumor-specificity. Docetaxel showed one order of magnitude higher TSM, but two orders of magnitude lower TSE than Compounds A and B. Compounds A and B showed higher TSM, TSE, and TSN values than doxorubicin, 5-FU, and cisplatin, damaging OSCC cells at concentrations that do not affect the viability of normal epithelial and neuronal cells. QSAR prediction based on the Tox21 database suggested that Compounds A and B may inhibit the signaling pathway of estrogen-related receptors.
Insights
Two novel styrylchromone derivatives, Compounds A and B, demonstrate superior tumor-specificity against oral cancer. They exhibit reduced toxicity to normal cells compared to existing chemotherapy drugs.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Adverse events like oral mucositis and neurotoxicity limit current anti-cancer drug efficacy.
- Two 3-styrylchromone derivatives, Compound A and Compound B, previously showed high tumor-specificity against oral squamous cell carcinoma (OSCC).
- Further evaluation was conducted to compare their tumor specificity and neurotoxicity against established chemotherapy agents.
Purpose of the Study:
- To confirm the superior tumor-specificity of Compounds A and B against OSCC.
- To evaluate and compare the neurotoxicity of Compounds A and B with common anti-cancer drugs.
- To investigate potential mechanisms of action, including inhibition of estrogen-related receptors.
Main Methods:
- Tumor specificity (TSM, TSE, TSN) was calculated as the ratio of CC50 values in normal cells (mesenchymal, epithelial, neuronal) to OSCC cells.
- Compounds A and B were compared with 65 newly synthesized derivatives and four standard anti-cancer drugs (docetaxel, doxorubicin, 5-FU, cisplatin).
- Quantitative Structure-Activity Relationship (QSAR) prediction using the Tox21 database was employed.
Main Results:
- Compounds A and B exhibited significantly higher tumor specificity than newly synthesized derivatives.
- Compounds A and B demonstrated superior tumor specificity and lower epithelial cell toxicity compared to docetaxel.
- Compounds A and B showed higher tumor specificity (TSM, TSE, TSN) than doxorubicin, 5-FU, and cisplatin, sparing normal cells.
- QSAR analysis suggested Compounds A and B may inhibit estrogen-related receptor signaling pathways.
Conclusions:
- Compounds A and B possess prominent tumor-specificity for OSCC, outperforming existing chemotherapy drugs.
- These compounds exhibit a favorable safety profile, with reduced toxicity to normal oral epithelial and neuronal cells.
- Compounds A and B represent promising candidates for developing novel, safer anti-cancer therapies for oral cancer.
